PlainBillCongress, translated.Legislation. Context. Public interest.Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10040-10043)
Congressional Research Service
Version 00 · Introduced in Senate · Sep 14, 2005
Vaccines for the New Millennium Act of 2005 - Directs the President to establish a strategy to accelerate efforts to develop vaccines and microbicides for neglected diseases such as HIV/AIDS, malaria, and tuberculosis, which shall: (1) expand public-private partnerships; (2) create economic incentives for such vaccines' research, development, and manufacturing; (3) include the negotiation of advanced market commitments; (4) address related intellectual property and regulatory approval issues; (5) maximize U.S. capabilities to support clinical trials in developing countries; (6) expand the purchase and delivery of existing vaccines; and (7) address the challenges of advance delivery of vaccines in developing countries.
Directs the Secretary of the Treasury to: (1) enter into negotiations with the World Bank, the International Development Association, Global Alliance for Vaccines and Immunizations, and other interested parties to establish advanced market commitments to purchase such vaccines and microbicides; and (2) establish in the Treasury the Lifesaving Vaccine Purchase Fund.
Amends the Internal Revenue Code to establish business credits for: (1) vaccine research related to HIV/AIDS, malaria, tuberculosis, or certain infectious diseases afflicting developing countries; and (2) certain sales of lifesaving vaccines to nonprofit organizations, or to foreign governments or instrumentalities for distribution in developing countries.
Showing the opening paragraphs of the official summary.
Amends the Small Business Act to: (1) direct the Small Business Administration (SBA) to establish a four-year pilot program to encourage the development of such vaccines and microbicides, including program outreach activities; and (2) provide Small Business Innovation Research Program (SBIR) and Small Business Technology Transfer Program (STTR) funding for such vaccines and microbicides.
People & committees
Sen. Kerry, John F. [D-MA] · D–MA
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S10040-10043)
Sponsor introductory remarks on measure. (CR S10039-10040)
Introduced in Senate
Primary sources
Text links open the official source. We currently store references to these documents.
Source last updated: Dec 5, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze S.1698 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine S.1698 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine S.1698 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine S.1698 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.